Protalix BioTherapeutics (PLX +2.3%) reverses morning losses to gain on news that Brazilian...

|About: Protalix BioTherapeutics, Inc (PLX)|By:, SA News Editor

Protalix BioTherapeutics (PLX +2.3%) reverses morning losses to gain on news that Brazilian health authorities had given regulatory approval to Uplyso, a long-term enzyme replacement therapy for adults with Type I Gaucher disease. PLX has partnered with Pfizer (PFE +0.3%) to market and commercialise the drug worldwide, apart from Israel where it maintains exclusive rights.